Harnessing the power of the gut and the gut-brain axis holds enormous, transformational potential to improve human health. We are currently advancing a diverse portfolio of novel, oral small-molecule therapies across three areas: metabolism, gastrointestinal (GI) disease, and neurological disorders.
Therapeutic Areas of Focus
We are advancing a novel, oral approach to type 2 diabetes and obesity, two conditions of epidemic proportions in need of improved treatment options. Our platform enables rational, combinatorial approaches to induce secretion of a full spectrum of satiety hormones rather than targeting just one.
A defective gastrointestinal (GI) barrier is associated with multiple conditions of high unmet need, including inflammatory bowel disease, chemotherapy-induced gut injury, food allergies, and celiac disease. We are advancing novel, oral, non-immunosuppressive therapeutics to improve GI barrier function. Our multi-targeted approach involves improving epithelial cell homeostasis, restoring appropriate immune responses, and repairing secretory cell function.
We have made significant advances using our proprietary Human Genetics Platform to identify multiple targets for neurological disorders, including migraine. We continue to focus our research efforts on therapeutic areas of high unmet need.